Overview

A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited